Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis

Ulcerative Colitis Clinical Trial

Official title:

A Phase 2, Randomized, Double-Blinded, Placebo Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (MT-1303) in Subjects With Mild to Moderate Ulcerative Colitis (UC)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04857112
• Other study ID #: AMUC-2023
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: September 29, 2021
• Est. completion date: September 2024

Study information

• Verified date: December 2023
• Source: Bausch Health Americas, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will assess the efficacy and safety of oral MT-1303 compared to placebo at 12 weeks as the induction treatment in subjects with active mild to moderate ulcerative colitis (UC), as well as maintenance treatment with open-label MT-1303 for up to 36 weeks.

Description:

This is a Phase 2, randomized, double-blinded, placebo-controlled 3-arm, multi-center, parallel-group study with an open-label extension (OLE) period. The study includes a Screening Period (of up to 28 days) and a 12-week Double-Blind Period (Day 1 through Day 85) for all subjects. Subjects completing the Double-Blind Period through Day 85 will be provided the opportunity to continue in the OLE Period of the study to receive treatment through approximately one year. Subjects who do not participate in the OLE Period will be followed for 84 days in a Safety Follow-up Period.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 322
• Est. completion date: September 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subjects will be eligible if they are male or female aged between 18 to 75 years at time of consent (inclusive) with normal vital signs and a diagnosis of active mild ulcerative colitis (UC) (modified Mayo Score of 3 or 4) or moderate UC (modified Mayo Score of 5 to 8) confirmed at least 12 weeks prior to randomization by clinical and endoscopic evidence and corroborated by a histopathology report.

• Subjects must have an endoscopic subscore of =2 from and evidence of active UC extending =15 cm from the anal verge confirmed by a screening colonoscopy.

• If subjects are receiving oral or rectal 5-aminosalicylates (5-ASAs) or oral corticosteroids (=20 mg prednisolone equivalent) for treatment of their UC, they must be on a stable dose for at least 28 days prior to randomization.

• Subjects who complete the Double-Blind Period of the study who, in the opinion of the Investigator, would benefit from continued treatment, may participate in the Open Label Extension (OLE) Period.

Exclusion Criteria:

• Any of the following: a diagnosis of Crohn's disease, indeterminate colitis, colitis (pseudomembranous, microscopic, or ischemic) or coeliac disease, current or recent (within 12 weeks prior to randomization) evidence of fulminant colitis, proctitis (defined as a rectal inflammation within 15 cm from the anal verge), abdominal abscess, toxic megacolon, bowel obstruction, or bowel perforation; a history or evidence of any colonic resection or subtotal or total colectomy, ileostomy, colostomy, known fixed symptomatic stenosis of the intestine, unresected adenomatous colonic polyps, or colonic mucosal dysplasia.

• Clinically significant infections (e.g., pneumonia, pyelonephritis, or septicemia) within 4 weeks prior to randomization or previous clinically significant infections requiring hospitalization within 6 months prior to randomization, active or latent tuberculosis, infections of hepatitis B, hepatitis C, human immunodeficiency virus (HIV), or previous shingles outbreak.

• Active SARS-CoV-2 infection or complications related to COVID-19.

• A history of, or currently active, primary or secondary immunodeficiency, presence of progressive multifocal leukoencephalopathy (PML), or presence of demyelinating diseases.

• A history or evidence of two or more failures with biologic treatment for UC.

• Currently taking any medication for treatment of UC other than oral or rectal 5-ASAs (5-aminosalicylic acids) or oral corticosteroids (=20 mg prednisolone equivalent)

• Been taking enemas or suppositories (other than stable dose of 5-ASA) for treatment of UC within 2 weeks prior to the Screening Visit.

• Been taking an unstable dose of probiotics or antidiarrheals 2 weeks prior to the Screening Visit.

• Had recent myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure with hospitalization, Class III/IV heart failure, Mobitz Type II 2nd degree or 3rd degree atrioventricular (AV) block, sick sinus syndrome, prolonged QT interval, Wolff Parkinson White or other conduction abnormalities, low heart rate, ongoing treatment with Class I or Class III anti-arrhythmic drugs, heart-rate-lowering calcium-channel blockers, ß blockers or with any other drugs which can reduce the heart rate, have known high risk for QT/QTc prolongation, or have clinically significant abnormal findings in 12-lead ECG that the Investigator considers may jeopardize the subject's health.

• Forced expiratory volume in one second (FEV1) or forced expiratory vital capacity (FVC) <70% of predicted values at screening. For sites where DLCO (diffusing capacity of the lungs for carbon monoxide) will be assessed, the value (mL/min/mmHg) is < 80% of the predicted normal value for age, height, and gender.

• Macular oedema as assessed by OCT (Optical Coherence Tomography).

• History of non-response or treatment failure with MT-1303 or other sphingosine 1 phosphate (S1P) receptor modulators.

• Fecal microbiota transplantation (FMT) within 12 months prior to the Screening Visit.

• Any of the following laboratory abnormalities:

• Hemoglobin (Hb) <9.0 g/dL.

• White blood cell (WBC) count <3.50 × 109/L (<3,500/µL).

• Neutrophil count <1.50 × 109/L (<1,500/µL).

• Lymphocyte count <0.80 × 109/L (<800/µL).

• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 × the upper limit of normal (ULN).

• Bilirubin >1.5 x the ULN; subjects with Gilbert's syndrome may be enrolled with total bilirubin up to 5.0 mg/dl.

• Positive stool tests for enteric pathogens, pathogenic ova or parasites, or Clostridium difficile (C. difficile) during the Screening Period. If subject has a history of recent C. difficile infection (within 60 days prior to Screening Visit), they should not be considered for study enrollment until subject has been treated for C. difficile and is symptom free for at least 14 days prior to the Screening Visit.

• Any physical or mental conditions which would interfere with the study participation, collection of data, or study completion as determined by the Investigator.

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Ulcer
• Ulcerative Colitis

Intervention

Drug:
• Low Dose MT-1303
MT-1303 loading dose of 0.4 mg once daily (QD) (Day 1-14) then maintenance dose of 0.2 mg QD (Day 15-85)
• High Dose MT-1303
MT-1303 loading dose of 0.8 mg QD (Day 1-14) then maintenance dose of 0.4 mg QD (Day 15-85)
• Placebo
Matching placebo, QD (Day 1-85)

Locations

Country	Name	City	State
United States	Bausch Site 025	Chandler	Arizona
United States	Bausch Site 011	Chicago	Illinois
United States	Bausch Site 014	El Paso	Texas
United States	Salix Site 002	Freehold	New Jersey
United States	Bausch Site 020	Glenview	Illinois
United States	Bausch Site 018	Houston	Texas
United States	Bausch Site 019	Houston	Texas
United States	Bausch Site 008	Lafayette	Louisiana
United States	Salix Site 004	Los Angeles	California
United States	Bausch Site 013	Maitland	Florida
United States	Bausch Site 017	Mentor	Ohio
United States	Bausch Site 022	Metairie	Louisiana
United States	Bausch Site 024	Miami	Florida
United States	Salix Site 005	Miramar	Florida
United States	Bausch Site 021	Oklahoma City	Oklahoma
United States	Salix Site 003	Rancho Cucamonga	California
United States	Salix Site 007	Rialto	California
United States	Salix Site 001	Shreveport	Louisiana
United States	Salix Site 010	Snellville	Georgia
United States	Bausch Site 012	Suffolk	Virginia
United States	Bausch Site 023	Tucson	Arizona
United States	Salix Site 006	Ventura	California

Sponsors (1)

Lead Sponsor	Collaborator
Bausch Health Americas, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in the modified Mayo Score at Day 85	The modified Mayo Score for ulcerative colitis disease activity provides an assessment of disease severity and can be used to monitor subjects during therapy. Scoring is accomplished by summation of subscores for endoscopic findings, stool frequency, and rectal bleeding, with higher scores indicating worse severity. Each subscore ranges from 0 to 3. The modified Mayo Score is defined as the sum of the endoscopy findings subscore + stool frequency subscore + rectal bleeding subscore, with a range from 0 to 9.	Baseline to Day 85
Secondary	The proportion of subjects with endoscopic improvement at Day 85	The Mayo endoscopic subscore ranges from 0 to 3, with higher scores indicating worse severity. Endoscopic improvement is a Mayo endoscopic subscore of =1.	Baseline to Day 85
Secondary	The change from Baseline in the 2-component Mayo Score at Day 85.	2-component Mayo scoring is accomplished by summation of subscores for endoscopic findings and rectal bleeding, with higher scores indicating worse severity. Each subscore ranges from 0 to 3. The 2-component Mayo Score is the sum of the rectal bleeding plus endoscopic subscores, with a range from 0 to 6.	Baseline to Day 85
Secondary	The proportion of subjects with clinical remission at Day 85 based on the modified Mayo Score	The modified Mayo Score for ulcerative colitis disease activity provides an assessment of disease severity and can be used to monitor subjects during therapy. Scoring is accomplished by summation of subscores for endoscopic findings, stool frequency, and rectal bleeding, with higher scores indicating worse severity. Each subscore ranges from 0 to 3.; Remission is defined as follows: Endoscopy subscore of =1 (excludes friability); and; Rectal bleeding subscore of 0; and; At least one-point decrease in stool frequency subscore from Baseline to achieve a stool frequency subscore of =1.	Baseline to Day 85